SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Chatzidionysiou Katerina)
 

Search: WFRF:(Chatzidionysiou Katerina) > Anakinra or tociliz...

  • Sundén-Cullberg, JonasKarolinska Institutet,Karolinska Univ Hosp, Dept Infect Dis, Stockholm, Sweden.;Karolinska Inst, Div Infect Dis, Dept Med Huddinge, Stockholm, Sweden. (author)

Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trial

  • Article/chapterEnglish2023

Publisher, publication year, extent ...

  • Public Library of Science (PLoS),2023
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:liu-200872
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-200872URI
  • https://doi.org/10.1371/journal.pone.0295838DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-219336URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:238157348URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:155125569URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-525511URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Background: Anakinra and tocilizumab are used for severe Covid-19, but only one previous randomized controlled trial (RCT) has studied both. We performed a multi-center RCT comparing anakinra or tocilizumab versus usual care (UC) for adults at high risk of deterioration.Methods: The study was conducted June 2020 to March 2021. Eligibility required ≥ 5 liters/minute of Oxygen to maintain peripheral oxygen saturation at ≥ 93%, CRP > 70 mg/L, ferritin > 500 μg/L and at least two points where one point was awarded for lymphocytes < 1x 109/L; D-dimer ≥ 0.5 mg/L and; lactate dehydrogenase ≥ 8 microkatal/L. Patients were randomly assigned 1:1:1 to receive either a single dose of tocilizumab (8 mg/kg) or anakinra 100 mg IV QID for seven days or UC alone. The primary outcome was time to recovery.Results: Recruitment was ended prematurely when tocilizumab became part of usual care. Out of a planned 195 patients, 77 had been randomized, 27 to UC, 28 to anakinra and 22 to tocilizumab. Median time to recovery was 15, 15 and 11 days. Rate ratio for recovery for UC vs anakinra was 0.91, 0.47 to 1.78, 95% [CI], p = 0.8 and for UC vs tocilizumab 1.13, 0.55 to 2.30; p = 0.7. There were non-significant trends favoring tocilizumab (and to limited degree anakinra) vs UC for some secondary outcomes. Safety profiles did not differ significantly.Conclusion: Premature closure of trial precludes firm conclusions. Anakinra or tocilizumab did not significantly shorten time to clinical recovery compared to usual care. (IMMCoVA, NCT04412291, EudraCT: 2020-00174824).

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Chen, PuranCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden,Karolinska Inst, Dept Med Huddinge, Ctr Infect Med, Stockholm, Sweden. (author)
  • Häbel, HenrikeDivision of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden,Karolinska Inst, Inst Environm Med, Div Biostat, Stockholm, Sweden. (author)
  • Skorup, PaulUppsala universitet,Infektionsmedicin(Swepub:uu)pausk660 (author)
  • Janols, HelenaUppsala universitet,Infektionsmedicin(Swepub:uu)helja415 (author)
  • Rasmuson, Johan,1977-Umeå universitet,Institutionen för klinisk mikrobiologi,Infection and Immunology, Department of Clinical Microbiology, Umeå University, Umeå, Sweden,Umeå Univ, Dept Clin Microbiol, Infect & Immunol, Umeå, Sweden.(Swepub:umu)janhan97 (author)
  • Niward, Katarina,1971-Linköpings universitet,Medicinska fakulteten,Avdelningen för inflammation och infektion,Region Östergötland, Infektionskliniken i Östergötland,Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden,Linköping Univ, Dept Biomed & Clin Sci, Linköping, Sweden.(Swepub:liu)katni01 (author)
  • Östholm Balkhed, Åse,1972-Linköpings universitet,Medicinska fakulteten,Avdelningen för inflammation och infektion,Region Östergötland, Infektionskliniken i Östergötland,Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden,Linköping Univ, Dept Biomed & Clin Sci, Linköping, Sweden.(Swepub:liu)aseos46 (author)
  • Chatzidionysiou, KaterinaRheumatology Division, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden,Karolinska Inst, Karolinska Univ Hosp, Div Rheumatol, Dept Med Solna, Stockholm, Sweden. (author)
  • Asgeirsson, HilmirDepartment of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden, Division of Infectious Diseases, Department of Medicine Huddinge, Karolinska Institute, Stockholm, Sweden,Karolinska Univ Hosp, Dept Infect Dis, Stockholm, Sweden.;Karolinska Inst, Div Infect Dis, Dept Med Huddinge, Stockholm, Sweden. (author)
  • Blennow, OlaDepartment of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden, Division of Infectious Diseases, Department of Medicine Huddinge, Karolinska Institute, Stockholm, Sweden,Karolinska Univ Hosp, Dept Infect Dis, Stockholm, Sweden.;Karolinska Inst, Div Infect Dis, Dept Med Huddinge, Stockholm, Sweden. (author)
  • Parke, ÅsaDepartment of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden, Division of Infectious Diseases, Department of Medicine Huddinge, Karolinska Institute, Stockholm, Sweden,Karolinska Univ Hosp, Dept Infect Dis, Stockholm, Sweden.;Karolinska Inst, Div Infect Dis, Dept Med Huddinge, Stockholm, Sweden. (author)
  • Svensson, Anna-KarinDepartment of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden, Division of Infectious Diseases, Department of Medicine Huddinge, Karolinska Institute, Stockholm, Sweden,Karolinska Univ Hosp, Dept Infect Dis, Stockholm, Sweden.;Karolinska Inst, Div Infect Dis, Dept Med Huddinge, Stockholm, Sweden. (author)
  • Muvva, Jagadeeswara RaoCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden,Karolinska Inst, Dept Med Huddinge, Ctr Infect Med, Stockholm, Sweden. (author)
  • Ljunggren, Hans-GustavCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden,Karolinska Inst, Dept Med Huddinge, Ctr Infect Med, Stockholm, Sweden. (author)
  • Horne, Anna-CarinKarolinska Institutet,Karolinska Univ Hosp, Theme Childrens & Womens Hlth, Stockholm, Sweden. (author)
  • Ådén, UlrikaDepartment of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden,Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden. (author)
  • Henter, Jan-IngeChildhood Cancer Research Unit, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden,Karolinska Inst, Dept Womens & Childrens Hlth, Childhood Canc Res Unit, Stockholm, Sweden. (author)
  • Sönnerborg, AndersDepartment of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden,Karolinska Univ Hosp, Dept Infect Dis, Stockholm, Sweden.;Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden. (author)
  • Vesterbacka, JanDepartment of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden, Division of Infectious Diseases, Department of Medicine Huddinge, Karolinska Institute, Stockholm, Sweden,Karolinska Univ Hosp, Dept Infect Dis, Stockholm, Sweden.;Karolinska Inst, Div Infect Dis, Dept Med Huddinge, Stockholm, Sweden. (author)
  • Nowak, PiotrDepartment of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden, Division of Infectious Diseases, Department of Medicine Huddinge, Karolinska Institute, Stockholm, Sweden,Karolinska Univ Hosp, Dept Infect Dis, Stockholm, Sweden.;Karolinska Inst, Div Infect Dis, Dept Med Huddinge, Stockholm, Sweden. (author)
  • Lampa, JonRheumatology Division, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden,Karolinska Inst, Karolinska Univ Hosp, Div Rheumatol, Dept Med Solna, Stockholm, Sweden. (author)
  • Karolinska InstitutetKarolinska Univ Hosp, Dept Infect Dis, Stockholm, Sweden.;Karolinska Inst, Div Infect Dis, Dept Med Huddinge, Stockholm, Sweden. (creator_code:org_t)

Related titles

  • In:PLOS ONE: Public Library of Science (PLoS)18:121932-6203

Internet link

Find in a library

  • PLOS ONE (Search for host publication in LIBRIS)

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view